Explore a treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+
Discuss efficacy and safety results from QuANTUM-First, which was a phase 3, randomized, double-blind, placebo-controlled trial exploring VANFLYTA in patients with newly diagnosed FLT3-ITD+ AML Rami Komrokji, MD Senior Member & Professor of Oncologic Sciences Vice Chair-Malignant Hematology Department Moffitt Cancer Center Bhavana (Tina) Bhatnagar, DO Director of Hematology and Medical Oncology Associate Professor of Medicine West Virginia University Cancer Institute – Wheeling Hospital This program is